ArticleCell2020
Psychedelic Psychiatry's Brave New World.
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review.Journal of clinical psychology · 2026Pooled it
- Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.Translational psychiatry · 2025Pooled it
- Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.Translational psychiatry · 2024Pooled it
- Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.CNS drugs · 2022Pooled it
- Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions.Frontiers in psychology · 2022Pooled it
- A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.Nature medicine · 2026Trial
- Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.Translational psychiatry · 2025Trial
- Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.Molecular psychiatry · 2025Trial
- Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.Translational psychiatry · 2023Trial
- Increased global integration in the brain after psilocybin therapy for depression.Nature medicine · 2022Trial
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.Journal of clinical psychopharmacologyTrial
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Molecular psychiatry · 2026Review
- Mechanistic Basis for 5-HTNature communications · 2026Article
- Contribution of the Serotonin 5-HTNeuropsychopharmacology reports · 2026Article
- Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.Journal of psychopharmacology (Oxford, England) · 2026Article
- Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors.bioRxiv : the preprint server for biology · 2026Article
- Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
Indexed as
Identifiers
32243793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.